All News
Oligoarticular vs. Polyarticular Psoriatic Arthritis
A psoriatic arthritis (PsA) cohort analysis reveals many similarities and few distinctions between those who present with oligoarticular and polyarticular PsA.
Read ArticleSustained Effectiveness of mRNA Vaccines Against COVID-19 Hospitalizations
The CDC has reported that mRNA vaccine effectiveness against COVID-19–associated hospitalizations was sustained over 24 weeks; but there is evidence of waning protection amongst the immunosuppressed.
Read ArticleEULAR Points on Managing Difficult Rheumatoid Arthritis
A EULAR task force has promulgated several points to consider in managing difficult-to-treat RA. These "points" are unique in directing the rheumatologist's attention to the potential for misdiagnosis and the impact of comorbid conditions on what is perceived as poorly controlled RA.
Read ArticleHHS, FDA & CDC Joint Recommendation on COVID Booster
Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people.
Read ArticleTocilizumab in Refractory Skin and Joint Scleroderma
The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc) and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization.
Read ArticleInflammatory Arthritis Impairs Male Fertility
A new study in Annals of Rheumatic Disease shows that inflammatory arthritis (IA) may impair male fertility, especially during the peak reproductive age when lower fertility rates, higher childlessness rates and more fertility problems were seen.
Read ArticleACR Update on Tocilizumab Shortages
The American College of Rheumatology (ACR) is actively engaged with the FDA Center for Drug Evaluation and Research (CDER) drug shortage team as they work with the manufacturer to resolve current shortages of tocilizumab (Actemra).
Read ArticleNon-Serious Infection Risk with Biologics in RA
Nonserious infections (NSI) comprise the bulk of all infections seen with biologic therapies; new data from British Society for Rheumatology Biologics Register for Rheumatoid Arthritis shows that while NSI are more common than serious infections, the predictors of NSI are the same as serious infections.
Read Article
Links:

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:

Links:

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:


k dao KDAO2011 ( View Tweet)

Peter Nash drpnash ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)